ArticleBMC infectious diseases2026
Drug-induced liver injury during the intensive phase of a fixed-dose daily regimen of anti-tuberculosis therapy: a cohort study from southern India.
Article in BMC infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Mentorship for research on TB in India: a course on Public Health Implementation Strengthening and Operational Research (MPHISOR).Public health action · 2026Article
- Feasibility of tuberculosis drug-induced liver injury screening under programme settings in Southern India.Public health action · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
22 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAnti-tuberculosis drug-induced liver injury (AT-DILI) is a major adverse event associated with significant morbidity and mortality. Limited real-world evidence exists in India on the incidence and risk factors of AT-DILI after switching over from an intermittent to a daily regimen involving the 4-drug fixed-dose combination (4FDC-ATT) in India. This study aimed to estimate the incidence and predictors of AT-DILI.
methodsA cohort study was conducted among adults with TB (≥ 18y) initiated on 4FDC-ATT between 01 September and 15 December 2024 across 5 tertiary care centers and 13 peripheral health institutes (PHI) in 2 districts of Tamil Nadu, a southern Indian state. The AT-DILI was diagnosed according to the Indian Drug-Induced Liver Injury Network criteria, which consider higher serum concentrations of aspartate aminotransferase, alanine aminotransferase, alkaline phosphatase, total bilirubin, and the presence or absence of clinical symptoms (nausea, vomiting, abdominal pain, or loss of appetite). The Cox proportional hazards model was used to calculate the adjusted hazard ratio for predictors of AT-DILI.
resultsOf 435 participants recruited at the baseline, 265 were followed up till 8 weeks. Baseline characteristics of participants who completed the study or were lost to follow-up were comparable. A majority of AT-DILI cases occurred within 2 weeks, and the overall prevalence at eight weeks is 4.9% (95% CI: 3.6-6.2). A significantly higher proportion of the AT-DILI patient group reported clinical symptoms at baseline than the others. Smokeless tobacco use (aHR = 4.9, 95% CI: 1.2-20.05) and pedal edema (aHR = 13.7, 95% CI: 2.5-75.6) at baseline were observed as significant predictors of AT-DILI.
conclusionsEarly onset of AT-DILI necessitates baseline and scheduled assessment of liver functions during the intensive phase, particularly among those with symptoms. Integrating LFT monitoring into the national TB program is resource-intensive, but it can be scaled up in a phased manner. Future studies should evaluate the feasibility and cost-effectiveness, as it could enhance patient safety and treatment adherence.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.